Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Organon said it plans to release third quarter 2026 results via its regularly scheduled Form 10-Q filing with the SEC, accompanied by a same-day Form 8-K disclosing certain non-GAAP measures and their reconciliations. The company has suspended its quarterly earnings calls during the pendency of the previously announced acquisition by Sun Pharmaceutical Industries, announced April 26, 2026.
Key figures
- Earnings call status
- suspended during pendency of Sun Pharma acquisition
- Q3 milestone expense expected
- No
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.